O	0	8	Efficacy
O	9	11	of
O	12	13	a
O	14	22	combined
B-intervention	23	34	alendronate
I-intervention	35	38	and
I-intervention	39	49	calcitriol
I-intervention	50	55	agent
I-intervention	56	57	(
I-intervention	57	66	Maxmarvil
I-intervention	66	67	®
I-intervention	67	68	)
O	69	71	in
B-ethinicity	72	78	Korean
B-eligibility	79	93	postmenopausal
I-eligibility	94	99	women
I-eligibility	100	104	with
I-eligibility	105	110	early
I-eligibility	111	117	breast
I-eligibility	118	124	cancer
I-eligibility	125	134	receiving
I-eligibility	135	144	aromatase
I-eligibility	145	154	inhibitor
O	154	155	:
O	156	157	a
O	158	164	double
O	164	165	-
O	165	170	blind
O	170	171	,
O	172	182	randomized
O	182	183	,
O	184	191	placebo
O	191	192	-
O	192	202	controlled
O	203	208	study
O	208	209	.

O	210	213	The
O	214	217	use
O	218	220	of
O	221	230	aromatase
O	231	240	inhibitor
O	241	242	(
O	242	244	AI
O	244	245	)
O	246	248	in
O	249	263	postmenopausal
O	264	269	women
O	270	274	with
O	275	282	hormone
O	283	291	receptor
O	292	293	(
O	293	295	HR
O	295	296	)
O	296	297	-
O	297	305	positive
O	306	311	early
O	312	318	breast
O	319	325	cancer
O	326	327	(
O	327	330	EBC
O	330	331	)
O	332	340	produces
O	341	342	a
O	343	354	deleterious
O	355	361	effect
O	362	364	on
O	365	369	bone
O	370	374	mass
O	375	378	and
O	379	381	an
O	382	390	increase
O	391	393	in
O	394	403	fractures
O	403	404	.

O	405	412	Several
O	413	420	studies
O	421	426	using
O	427	438	intravenous
O	439	454	bisphosphonates
O	455	459	have
O	460	465	shown
O	466	475	effective
O	476	486	management
O	487	489	of
O	490	492	AI
O	492	493	-
O	493	500	induced
O	501	505	bone
O	506	510	loss
O	510	511	.

O	512	514	To
O	515	524	determine
O	525	532	whether
O	533	534	a
O	535	540	lower
O	541	547	dosage
O	548	550	in
O	551	555	oral
O	556	560	form
O	561	569	combined
O	570	574	with
O	575	585	calcitriol
O	586	589	can
O	590	601	effectively
O	602	608	manage
B-condition	609	611	AI
I-condition	611	612	-
I-condition	612	619	induced
I-condition	620	624	bone
I-condition	625	629	loss
O	629	630	,
O	631	633	we
O	634	643	performed
O	644	645	a
O	646	656	randomized
O	656	657	,
O	658	664	double
O	664	665	-
O	665	670	blind
O	670	671	,
O	672	683	prospective
O	683	684	,
O	685	692	placebo
O	692	693	-
O	693	703	controlled
O	704	706	24
O	706	707	-
O	707	711	week
O	712	717	trial
O	718	722	with
O	723	724	a
O	725	736	combination
O	737	739	of
O	740	751	alendronate
O	752	755	and
O	756	757	0
O	757	758	.
O	758	759	5
O	759	760	-
O	760	761	µ
O	761	762	g
O	763	765	of
O	766	776	calcitriol
O	777	782	daily
O	783	785	to
O	786	788	HR
O	788	789	-
O	789	797	positive
O	798	801	EBC
O	802	810	patients
O	810	811	.

O	812	813	A
O	814	819	total
O	820	822	of
B-total-participants	823	825	98
O	826	832	Korean
O	833	847	postmenopausal
O	848	853	women
O	854	858	with
O	859	861	HR
O	861	862	-
O	862	870	positive
O	871	874	EBC
O	875	878	who
O	879	887	received
O	888	893	daily
O	894	896	AI
O	896	897	,
O	898	905	calcium
O	906	909	and
O	910	917	vitamin
O	918	919	D
O	920	924	were
O	925	933	randomly
O	934	942	assigned
O	943	945	to
O	946	947	5
O	947	948	-
O	948	950	mg
O	951	953	of
O	954	965	alendronate
O	966	969	and
O	970	971	0
O	971	972	.
O	972	973	5
O	973	974	-
O	974	975	µ
O	975	976	g
O	977	979	of
O	980	990	calcitriol
O	991	992	(
O	992	1001	Maxmarvil
O	1001	1002	®
O	1002	1003	)
O	1004	1006	or
B-control	1007	1014	placebo
O	1015	1021	groups
O	1021	1022	.

O	1023	1026	The
O	1027	1031	bone
O	1032	1039	mineral
O	1040	1047	density
O	1048	1049	(
O	1049	1052	BMD
O	1052	1053	)
O	1054	1057	and
O	1058	1066	turnover
O	1067	1074	markers
O	1075	1079	were
O	1080	1088	measured
O	1088	1089	.

B-outcome	1090	1092	At
I-outcome	1093	1097	week
I-outcome	1098	1100	24
O	1100	1101	,
O	1102	1105	the
O	1106	1116	difference
O	1117	1119	in
B-outcome	1120	1126	lumbar
I-outcome	1127	1130	BMD
O	1131	1138	between
O	1139	1142	the
O	1143	1149	groups
O	1150	1153	was
O	1154	1155	3
O	1155	1156	.
O	1156	1157	0
O	1157	1158	%
O	1159	1160	(
O	1160	1161	p
O	1162	1163	<
O	1164	1165	0
O	1165	1166	.
O	1166	1169	005
O	1169	1170	)
O	1170	1171	.

O	1172	1175	The
B-outcome	1176	1184	increase
I-outcome	1185	1187	in
I-outcome	1188	1189	C
I-outcome	1189	1190	-
I-outcome	1190	1201	telopeptide
I-outcome	1202	1207	after
I-outcome	1208	1210	24
I-outcome	1211	1216	weeks
O	1217	1220	was
O	1221	1234	significantly
O	1235	1239	less
O	1240	1242	in
O	1243	1246	the
O	1247	1256	Maxmarvil
O	1257	1262	group
O	1263	1271	compared
O	1272	1274	to
O	1275	1279	that
O	1280	1282	in
O	1283	1286	the
O	1287	1294	placebo
O	1295	1300	group
O	1301	1302	(
B-iv-cont-mean	1302	1304	35
I-iv-cont-mean	1304	1305	.
I-iv-cont-mean	1305	1306	2
O	1307	1308	±
B-iv-cont-sd	1309	1311	17
I-iv-cont-sd	1311	1312	.
I-iv-cont-sd	1312	1313	5
I-iv-cont-sd	1313	1314	%
O	1315	1317	vs
O	1317	1318	.
B-cv-cont-mean	1319	1322	109
I-cv-cont-mean	1322	1323	.
I-cv-cont-mean	1323	1324	8
O	1325	1326	±
B-cv-cont-sd	1327	1329	28
I-cv-cont-sd	1329	1330	.
I-cv-cont-sd	1330	1331	6
I-cv-cont-sd	1331	1332	%
O	1332	1333	,
O	1334	1335	p
O	1336	1337	<
O	1338	1339	0
O	1339	1340	.
O	1340	1342	05
O	1342	1343	)
O	1343	1344	.

O	1345	1348	Our
O	1349	1354	study
O	1355	1367	demonstrates
O	1368	1372	that
O	1373	1374	a
O	1375	1386	combination
O	1387	1389	of
O	1390	1391	5
O	1391	1392	-
O	1392	1394	mg
O	1395	1406	alendronate
O	1407	1410	and
O	1411	1412	0
O	1412	1413	.
O	1413	1414	5
O	1414	1415	-
O	1415	1416	µ
O	1416	1417	g
O	1418	1428	calcitriol
O	1429	1431	is
O	1432	1441	effective
O	1442	1444	to
O	1445	1452	prevent
O	1453	1457	bone
O	1458	1462	loss
O	1463	1466	due
O	1467	1469	to
O	1470	1472	AI
O	1473	1475	in
O	1476	1482	Korean
O	1483	1497	postmenopausal
O	1498	1503	women
O	1504	1508	with
O	1509	1512	EBC
O	1512	1513	.
